# PCS-XI (NCT05820633)

> Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05820633
- Phase: NA
- Status: SUSPENDED
- Sponsor: CHU de Quebec-Universite Laval
- Conditions: Prostate Cancer; Node; Prostate; Radiotherapy Side Effect
- Interventions: Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS); Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):; Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM); Report and compare changes in a non-inferiority analysis of the toxicities reported according to the Common Terminology Criteria for Adverse Events (CTCAE); Report and compare the biochemical disease free survival (bDFS); Report and compare the disease free survival (DFS); Report and compare the metastase free survival (MFS); Report and compare the overall survival (OS)
- Enrollment: 500
- Primary outcome: Non-inferiority analysis of early change in genito-urinary (GU) toxicities induced.
- Primary outcome: Non-inferiority analysis of early change in reported Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire.
- Primary outcome: Non-inferiority analysis of late change in genito-urinary (GU) toxicities induced.
- Primary outcome: Non-inferiority analysis of late change in reported Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire.
- Primary outcome: Non-inferiority analysis of early change in sexual health.
- Primary outcome: Non-inferiority analysis of late change in sexual health.
- Primary outcome: Non-inferiority analysis of early change in toxicities reporte via the Common Terminology Criteria for Adverse Events (CTCAE).
- Primary outcome: Non-inferiority analysis of late change in toxicities reporte via the Common Terminology Criteria for Adverse Events (CTCAE).

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 14
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=pcs-xi-nct05820633

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05820633", "email": "<work email>"}; the inbox owner confirms by the emailed link.